Obesity evidence dossier
MDR-001
A differentiated oral small-molecule GLP-1RA with company-reported mid-stage efficacy; Phase 3 is the key confirmation step.
Total weight loss
10.3%
NCT06606483 · highest-response arm; 90–180 mg twice daily studied · week 24 · Analysis not fully specified
Placebo-adjusted
7.8%
Difference from placebo in the same study when reported.
Study context
AI-designed, orally bioavailable small-molecule GLP-1 receptor agonist described by MindRank as biased/selective and beta-arrestin-2 selective./Adults with obesity or overweight in China; diabetes exclusion not specified in this source/317 participants across the study/24-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
NCT06606483 · highest-response arm; 90–180 mg twice daily studied · 24 weeks
Adults with obesity or overweight in China; diabetes exclusion not specified in this source. 317 participants across the study (not this dose arm alone).
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally.
- Average weight loss
- 10.3%
- Placebo group
- 2.5% loss
- Beyond placebo
- 7.8 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
The release gives the maximum response but does not identify its exact dose arm or formal estimand. Score is provisional.
Score: 70% × 41.3 total-loss points + 30% × 39.0 beyond-placebo points = 41/100, rounded. Conversion scales
MindRank, Phase 2b topline ↗Phase 2b · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
NCT06606483: Analysis not fully specified. The release gives the maximum response but does not identify its exact dose arm or formal estimand. Score is provisional.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Most treatment-emergent adverse events were mild-to-moderate gastrointestinal symptoms, including nausea, vomiting, and diarrhea; reported treatment-emergent-adverse-event discontinuation was 0.8%, with no treatment-related serious adverse events.
Main cautions
Company-reported topline data have not been replaced by a full peer-reviewed Phase 2b publication; long-term safety remains under Phase 3 evaluation.
Upcoming catalyst
What to watch next
52-week Phase 3 MOBILE efficacy and safety results.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT07274137
Phase 3
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
MindRank AI Ltd
Non-diabetic obesity
Dec 22, 2025
NCT07110766
Phase 1
Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight
MindRank AI Ltd
Non-diabetic obesity
Aug 8, 2025
NCT06778850
Phase 2
A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants
MindRank AI Ltd
Healthy volunteer
Mar 7, 2025